OraSure Technologies (NASDAQ:OSUR) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

OraSure Technologies, Inc. (NASDAQ:OSUR) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.90 and traded as high as $4.19. OraSure Technologies shares last traded at $4.15, with a volume of 808,637 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Stock Performance

The business has a fifty day moving average of $3.29 and a 200-day moving average of $2.90. The company has a market capitalization of $285.73 million, a P/E ratio of -3.99 and a beta of 1.02.

Insider Buying and Selling

In related news, Director Steven Kyle Boyd acquired 25,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the purchase, the director owned 113,462 shares in the company, valued at approximately $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Manner Carrie Eglinton acquired 32,300 shares of the company’s stock in a transaction on Friday, March 20th. The shares were bought at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief executive officer owned 2,190,874 shares in the company, valued at approximately $6,419,260.82. This represents a 1.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 158,643 shares of company stock worth $470,657 in the last ninety days. Corporate insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On OraSure Technologies

Several large investors have recently bought and sold shares of the stock. Sei Investments Co. lifted its stake in OraSure Technologies by 16.4% during the 3rd quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock valued at $103,000 after acquiring an additional 4,536 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in OraSure Technologies by 13.3% during the 4th quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 5,138 shares in the last quarter. Hsbc Holdings PLC lifted its stake in OraSure Technologies by 4.6% during the 1st quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier’s stock valued at $421,000 after acquiring an additional 6,218 shares in the last quarter. Peapod Lane Capital LLC lifted its stake in OraSure Technologies by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 674,033 shares of the medical instruments supplier’s stock valued at $2,164,000 after acquiring an additional 7,426 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in OraSure Technologies by 102.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 7,720 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.